CORRIGENDUM: Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen, Ahmad, A., Sheikh, S., Shah, T., Reddy, M., Prasad, B., Verma, K., Chandrakant, B., Paithankar, M., Kale, P., Solanki, R., Patel, R., Barkate, H. and Ahmad, I. Clinical And Translational Science, 9: 252–259. doi:10.1111/cts.12407.
The published version of this article noted that the authors declared no conflicts of interest. However, the following conflict should have been disclosed: A.A., S.S., and I.A. are employees of Jina Pharmaceuticals, the manufacturer of Endoxifen. The authors apologize for the oversight.